30 closest matches · ranked by relevance
Hemorrhage
Primary: Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of dTT or ECT — 100.0; 100.0; 100.0; 100.0 percentage
Atrial Fibrillation · Catheter Ablation
Primary: Time to Ambulation — 480; 316 minutes — p=<0.001
Atrial Fibrillation
Primary: The Number of Patients With Emergency Surgery and Major Bleeding Due to Fracture or Trauma. — 14; 35; 84 Number of Patients
Hemorrhage
Primary: Number of Participants With Drug-related Adverse Events (AEs) — 0 Participants
Acute Bleeding on Long-Term Anticoagulation Therapy · Hemorrhage · Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time)
Primary: Number of Participants Who Demonstrated Significant Reversal of INR Within 15 Minutes — 21; 33 Participants
Healthy
Primary: Subjects Achieving Complete Reversal of Anticoagulation (WBCT is ≤ 110% of Baseline) — 3; 7; 11; 11 Participants
Significant Bleeding Risk
Primary: Hemostatic Efficacy Rating by IEAB — 41; 50; 58; 47 Participants
Healthy
Primary: Subjects Achieving Complete Reversal of Anticoagulation (WBCT is ≤ 110% of Baseline) — 2; 9; 12; 12 Participants
Reversal of Anticoagulant Treatment
Primary: INR Response — 74; 31 Participants
Liver Fibrosis
Primary: Median Liver Stiffness Value — 7.70; 6.90 kPa — p=0.043
Coronary Artery Disease
Primary: P2Y12 Reaction Unit (PRU) — 284.1; 284.1; 39.1; 37.5 PRU
Venous Thromboembolism
Primary: Time Spent Per PT/INR Monitoring Encounter — 19.4; 47 minutes
Hemorrhage
Primary: Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Ecarin Clotting Time — 100.0; 100.0; 100.0 Percentage
Blood Coagulation Disorders · Acute Major Bleeding
Primary: Percentage of Participants Achieving Hemostatic Efficacy of Stopping an Ongoing Major Bleed — 72.4; 65.4 percentage of participants
Reversal of Coagulopathy
Primary: Percentage of Participants Achieving Hemostatic Efficacy During Surgery — 89.7; 75.3 percentage of participants
Anticoagulants · Atrial Fibrillation · Venous Thromboembolism
Primary: Percent Change in Time in Therapeutic Range (TTR) — 2.8; 0.5 percent change — p=<0.001
Hemorrhage
Primary: Percentage of Subjects With Drug-related Adverse Events — 0.0 Percentage of participants
Acute Hypoxemic Respiratory Failure · Anticoagulant-induced Bleeding · Thromboembolism
Primary: Number of Participants With Major Bleeding Events — 1; 4 Participants
Thromboembolism
Primary: Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE — 30; 27; 34; 32 Participants — p=<0.0001
Bleeding · Hemorrhage
Primary: INTEM HEPTEM and FIBTEM Test of the ROTEM Coagulation Analyzer — 98; 117; 178; 253 seconds
Bleeding
Primary: Efficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Parts I and II) — -18.39; -92.22; -44.75; -96.72 Percent change in anti-fXa activity — p=<0.0001
Atrial Fibrillation
Primary: Number of Participants With Adjudicated Major or Clinically Relevant Non-major Bleeding As First Event Defined by International Society on Thrombosis and Haemostasis…
Venous Thromboembolism
Primary: Percentage of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - Overall — 3.8 Percentage of VTE recurrence
Atrial Fibrillation
Primary: Number of Participants Who Experienced the Composite of All-cause Death, Stroke (VARC-2), and Major Bleeding (ISTH) in the Edoxaban Group Compared With Vitamin K…
Bleeding
Primary: Percent Change From Baseline In Anti-fXa Activity By FXa Inhibitor — -93.3; -94.1; -71.3; -75.41 Percent Change
Venous Thrombosis
Primary: Emax (Maximum Effect) on Prothrombin Time (PT) (Coagulation Test) — 4.393; 1.884; 1.573 ratio — p=<0.0001
Non-valvular Atrial Fibrillation
Primary: Event Rate Per 100 Participant-Years For First Occurrence of Stroke and Systemic Embolism Events After Index Date — 3.2; 1.67; 2.08; 1.79 Events Per 100…
Bleeding
Primary: Efficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Parts I and II) — -20.71; -93.86; -32.70; -92.34 Percent change in anti-fXa activity — p=<0.0001
Hemorrhage
Primary: Reversal of Dabigatran-induced Prolongation of Blood Coagulation Time — 0.0; 100.0; 0.0; 100.0 percentage of participants
Fibrillation, Atrial
Primary: Number of Participants With at Least One Event of Cerebral Neurologic Event, Systemic Thromboembolism, Death From Any Cause, and/or Major Bleeding Until the End of…